RADIOLABELLED ANTIBODY THERAPY OF ACUTE LEUKEMIA

急性白血病的放射性标记抗体治疗

• 批准号: 6269289
• 负责人: FREDERICK APPELBAUM
• 金额: $ 35.87万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-05-01 至 1999-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6269289
• 关键词: Macaca nemestrina; acute lymphocytic leukemia; acute myelogenous leukemia; acute nonlymphocytic leukemia; autologous transplantation; bone marrow transplantation; busulfan; clinical trials; colony stimulating factor; combination cancer therapy; cyclophosphamide; dogs; drug adverse effect; human subject; human therapy evaluation; interleukin 3; iodine; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide therapy; nuclear medicine; radiation therapy dosage; radionuclides; radiopharmacology; whole body irradiation dosage

The overall goal of project III is to evaluate the use of I-131- labeled anti-myeloid antibodies and autologous marrow transplantation as treatment for acute nonlymphocytic leukemia. This approach is based on the ability of labeled antibody to localize to the marrow space and the utility of external beam total body irradiation (TBI) with autologous marrow transplantation in treating ANL. We will initially measure the pharmacokinetics, biodistribution and associated radiation dosimetry of varying doses of I-131-labeled anti-myeloid antibodies in patients with ANL in second (or subsequent) remission. In patients in whom we achieve favorable dosimetry, we will evaluate the effects of increasing therapeutic doses of I- 131-labeled antibody with particular attention to the ability of the antibody-conjugate to ablate marrow, recovery of hematopoiesis following autologous transplantation, and the nature and extent of extramedullary toxicities. If favorable dosimetry is not achieved we will evaluate alternatives antibodies, forms of antibody (F(ab) or F(ab')2), or antibody infusion schedules.

项目三的总体目标是评估I-131-的使用情况